Small‐Molecule Kinase‐Inhibitor Target Assessment
Authors:
- 1 March 2005
- journal article
- concept
- Published by Wiley in ChemBioChem
- Vol. 6 (3) , 523-526
Abstract
The identification of the cellular targets of small‐molecule protein kinase inhibitors is a significant hurdle to assessing their therapeutic potential for many diseases. Here we review several biochemical and genetics‐based approaches to identifying inhibitor targets. We also describe a chemical‐genomics approach to kinase‐inhibitor target identification and validation that matches transcriptional signatures elicited by a drug of unknown specificity and those elicited by highly specific pharmacological inhibition of engineered candidate kinase targets.Keywords
This publication has 36 references indexed in Scilit:
- Kinase Inhibition with BAY 43–9006 in Renal Cell CarcinomaClinical Cancer Research, 2004
- A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)Cancer Research, 2004
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- Two Cyclin-Dependent Kinases Promote RNA Polymerase II Transcription and Formation of the Scaffold ComplexMolecular and Cellular Biology, 2004
- A Three-Hybrid Approach to Scanning the Proteome for Targets of Small Molecule Kinase InhibitorsChemistry & Biology, 2004
- A Three-Hybrid Approach to Scanning the Proteome for Targets of Small Molecule Kinase InhibitorsChemistry & Biology, 2004
- Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathwaysNature Biotechnology, 2003
- p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanolOncogene, 2002
- Specificity and mechanism of action of some commonly used protein kinase inhibitorsBiochemical Journal, 2000
- Drug target validation and identification of secondary drug target effects using DNA microarraysNature Medicine, 1998